Outcome of the Board Meeting dated May 23, 2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
The board approved the audited standalone financial results for Q4 and FY26 ended March 31, 2026. Full-year revenue grew 13.6% to ₹2,498.20 lakhs from ₹2,199.90 lakhs in FY25, but profit after tax collapsed to just ₹5.13 lakhs from ₹207.26 lakhs in the previous year—a decline of over 97%. Q4 alone reported a loss of ₹68.91 lakhs. The sharp profit decline appears driven by higher employee costs (₹877.68 lakhs vs ₹732.62 lakhs) and increased other expenses. The auditors issued an unmodified (clean) opinion. The board also appointed Mrs. Neetu Maurya as Company Secretary and Compliance Officer, M/s. Vishal J Bhanushali & Associates as Internal Auditor, and Mr. Vaibhav Odhekar as Additional Executive Director for 5 years. During the year, the company acquired Om Pathology Laboratory in Surat (effective February 2026) and the business of Aspira DNA Diagnostics Gujarat LLP (effective June 2025), creating goodwill of ₹330.56 lakhs. Cash and cash equivalents declined from ₹175.24 lakhs to ₹126.46 lakhs during the year.
The massive profit collapse despite revenue growth signals margin compression from rising costs, which could negatively impact the stock price. However, the clean audit opinion and strategic acquisitions may provide some comfort to investors. The appointment of an experienced executive director with tech and growth expertise could support future expansion plans.